Skip to main content
. 2022 Dec;17(12):1730–1741. doi: 10.2215/CJN.03790322

Figure 4.

Figure 4.

Cost-effectiveness acceptability curves for the United Kingdom, Germany, and Spain. The probability of dapagliflozin with standard therapy being cost effective at a given willingness-to-pay threshold versus standard therapy alone. The established willingness-to-pay threshold for each country is indicated by a vertical line from the y axis.